ÇмúÇà»ç

Korean Society of Gastrointestinal Cancer Research

Çмú´ëȸ ÀÚ·á½Ç

Á¦17ȸ ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ

¼¼Á¾´ëÇб³ ÄÁº¥¼Ç¼¾ÅÍ ÄÁº¥¼ÇȦ 2022-06-17

A Ȧ

Á¦17ȸ ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ
Session I Mini-review of ASCO/ESMO GI Cancer Symposium (What's new in 2022) ÁÂÀå: ±èÈ£°¢(´ë±¸°¡Å縯ÀÇ´ë), ÀÓÀ±Á¤(µ¿±¹ÀÇ´ë)
09:10-09:30 1. Esophageal/stomach cancer À̹®¿ø(ºÎ»êÀÇ´ë)
09:30-09:50 2. Colorectal cancer ±è¼ºÁß(Á¶¼±ÀÇ´ë)
09:50-10:10 3. Pancreatobiliary cancer ¾Èµ¿¿ø(¼­¿ïÀÇ´ë º¸¶ó¸Åº´¿ø)
Session II IASGO joint session : debate or controversial issues of GI cancer (English) ÁÂÀå: ¼Û½Ã¿µ(¿¬¼¼ÀÇ´ë), Kyoichi Takaori(Kyoto university)
10:40-11:05 1. Treatment of Obstructive Gastric Cancer with distant metastasis; Palliative Chemotherapy ±è¼ºÀº(°í½ÅÀÇ´ë)
11:05-11:30 2. Surgical Strategy for Stage IV Gastric Cancer; Neoadjuvant Chemotherapy followed by Curative Gastrectomy Sang Woong Lee(Osaka Medical and Pharmaceutical University)
11:30-11:55 3. Multi-modality treatment for oligometastatic pancreatic cancer : Surgical and local therapeutic concept from surgeon's view point Masayuki Sho (Nara Medical University)
11:55-12:20 4. Multi-modality treatment for oligometastatic pancreatic cancer : Conventional chemotherapy and immunotherapy from physician's view point Á¶Àη¡(¼­¿ïÀÇ´ë)
Session III Genomics and clinical application in GI cancers ÁÂÀå: ±è¼º¼ö(°¡Å縯ÀÇ´ë), ¹æ½Â¹Î(¿¬¼¼ÀÇ´ë)
13:20-13:45 1. Interpretation and clinical application of NGS(next generation sequencing) in GI cancer ¹Ú¼º¿­(GENOME INSIGHT Inc)
13:45-14:10 2. Practical implications of the molecular and immunologic classifications in colorectal cancer ¹èÁ¤¸ð(¼­¿ïÀÇ´ë º´¸®°ú)
14:10-14:35 3. Understanding and therapeutic application of glutamine metabolism in pancreatic cancer ÇÑÁ¤¹Î(¿¬¼¼´ë ¾àÇдëÇÐ)
14:35-15:00 4. Understanding subtype plasticity in pancreatic cancer ³ëÀç¼®(¿¬¼¼´ë »ýÈ­Çаú)
Session IV Controversies and advance in the management of non-metastatic pancreatobiliary cancer ÁÂÀå: ȲÁøÇõ(¼­¿ïÀÇ´ë), ¹Úº´±Ô(±¹¹Î°Ç°­º¸ÇèÀϻ꺴¿ø)
15:20-15:45 1. Neoadjuvant therapy for resectable/borderline resectable pancreatic cancer Á¶ÁßÇö(¿¬¼¼ÀÇ´ë)
15:45-16:10 2. Optimal treatment sequencing for Locally advanced pancreatic cancer À̵¿¿í(°æºÏÀÇ´ë)
16:10-16:35 3. Neoadjuvant/adjuvant therapy for biliary tract cancer ±èÀçȯ(¼­¿ïÀÇ´ë)
16:35-17:00 4. Novel radiation strategies for pancreatobiliary cancer ÀÌÀÍÀç(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)

B Ȧ

Á¦17ȸ ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ
Session I Free paper session ÁÂÀå: À̼öÅÃ(ÀüºÏÀÇ´ë), ÀÌ»óÇù(¼­¿ïÀÇ´ë)
09:10-09:20 Usefulness of in-stent radiofrequency ablation after occlusion of self-expandable metal stent in unresectable malignant biliary obstruction: Multicenter propensity-score matched study ¹Ú³²¿µ(°æÈñÀÇ´ë)
09:20-09:30 ÅëÇÕÀû ´ÜÀÏ ¼¼Æ÷ Àü»çü ºÐ¼®À» ÅëÇÏ¿© È®ÀÎµÈ ÃéÀå¾Ï ¼¼Æ÷ÀÇ ºÐÀÚ»ý¹°ÇÐÀû ¾ÆÇüÀÇ µ¿Àû ÀüÀÌ ÀÓ°¡¶÷(¿¬¼¼ÀÇ´ë)
09:30-09:40 ÃéÀå¾Ï Áø´Ü ÀÌÀü¿¡ ½ÃÇàµÈ CT ¿µ»ó¿¡¼­ ÈÄÇâÀûÀ¸·Î °üÂûµÈ ÃéÀå¾Ï ÀÇ½É ¼Ò°ß °íÈñµ¿(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø)
09:40-09:50 Incidence and risk factors of pancreatic cancer in patients with definite chronic pancreatitis: a multicenter retrospective study ±èÇý¸²(°¡Å縯ÀÇ´ë)
09:50-10:00 Risk factors of short safety margin after endoscopic submucosal dissection for early gastric cancer °­¼±Çü(Ãæ³²ÀÇ´ë)
10:00-10:10 Endoscopic submucosal dissection using a detachable assistant robot: a comparative in vivo feasibility study ±è»óÇö(°í·ÁÀÇ´ë)
10:10-10:20 Comparison of clinical outcomes: stenting as bridge to surgery versus surgery alone in colorectal cancer obstruction È«½Â¹Î(ºÎ»êÀÇ´ë)
Session II New diagnostic paradigm in GI disease (Combined session of KSGC, KCHUGR, KSNM) ÁÂÀå: ÀüÈÆÀç(°í·ÁÀÇ´ë), Á¤´ë¿µ(°¡Å縯ÀÇ´ë))
10:40-11:05 Updated diagnostic methodology in GI motility disorder Á¤±â¿í(¿ï»êÀÇ´ë)
11:05-11:30 Application of AI in endoscopy for GI cancer ¹æâ¼®(ÇѸ²ÀÇ´ë)
11:30-11:55 Application of AI in pathology for GI cancer ÀÌ°æºÐ(¼­¿ïÀÇ´ë º´¸®°ú)
11:55-12:20 Application of AI in radiology for GI cancer ±è³²±¹(¿ï»êÀÇ´ë À¶ÇÕÀÇÇаú)
Session III Plenary session ÁÂÀå: ¹Ú¼±ÀÚ(°í½ÅÀÇ´ë), ¹ÚÁ¤¿±(¿¬¼¼ÀÇ´ë)
13:20-13:32 Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Korean Multicenter Study ±è¼ÒÁ¤(¿¬¼¼ÀÇ´ë)
13:32-13:44 Associated factors of gastric and duodenal neuroendocrine neoplasms: a multicenter casecontrol study ³²±¤¿ì(´Ü±¹ÀÇ´ë)
13:44-13:56 Long-term Outcomes of Endoscopic Papillectomy for Ampullary High-grade Dysplasia or Earlystage Cancer: a Multicenter Retrospective Cohort Study in Korea À±½Â¹è(°¡Å縯ÀÇ´ë)
13:56-14:09 High expression of latexin can be a novel prognostic marker for pancreatic cancer ¹ÚÂùÈñ(¿¬¼¼ÀÇ´ë)
14:09-14:22 Single Cell RNA Sequencing Analysis and its Clinical Significance in Pancreatic Ductal Adenocarcinoma (PDAC) ±èÇý¹Î(¼º±Õ°üÀÇ´ë)
14:22-14:35 Analysis of risk factors for recurrence of distal bile duct cancer without lymph node metastasis after curative resection: Is adjuvant therapy really required? ±è¼ÒÁ¤(¿¬¼¼ÀÇ´ë)
14:35-14:48 Comparison of the Quantity and Size Distribution between Normal Cell Free DNA and Circulating Tumor DNA in Korean Colorectal Cancer Patients ±è»óÇö(°í·ÁÀÇ´ë)
14:48-15:00 Identification and Analysis of Circulating MicroRNAs expression profiles in XELOX Chemotherapy-induced Peripheral Neuropathy of Patients with Gastric Cancer ±èµ¿¿í(ºÎ»êÀÇ´ë)
Session IV Clinical advice needed in difficult situations of gastrointestinal cancer ÁÂÀå: ÁøÀ±ÅÂ(°í·ÁÀÇ´ë), ±èÇö¼ö(Àü³²ÀÇ´ë)
15:20-15:45 1. Peritoneal carcinomatosis: Cytoreductive surgery vs. HIPEC vs. PIPAC ¹é½ÂÇõ(¿¬¼¼ÀÇ´ë ´ëÀåÇ×¹®¿Ü°ú)
15:45-16:10 2. Malignant colorectal obstruction: surgery vs. stent ±èÁ¤È£(°¡ÃµÀÇ´ë)
16:10-16:35 3. Overcoming chemo-resistance in gastric cancer ¹®Èñ¼®(Ãæ³²ÀÇ´ë)
16:35-17:00 4. Endotherapy for cancer bleeding and post-operative complications Á¶¿µ½Å(¼øõÇâÀÇ´ë)